Quest for the right Drug
אוקסאאר פלוס OCSAAR PLUS (HYDROCHLOROTHIAZIDE, LOSARTAN POTASSIUM)
תרופה במרשם
תרופה בסל
נרקוטיקה
ציטוטוקסיקה
צורת מתן:
פומי : PER OS
צורת מינון:
טבליה : TABLETS
עלון לרופא
מינוניםPosology התוויות
Indications תופעות לוואי
Adverse reactions התוויות נגד
Contraindications אינטראקציות
Interactions מינון יתר
Overdose הריון/הנקה
Pregnancy & Lactation אוכלוסיות מיוחדות
Special populations תכונות פרמקולוגיות
Pharmacological properties מידע רוקחי
Pharmaceutical particulars אזהרת שימוש
Special Warning עלון לרופא
Physicians Leaflet
Adverse reactions : תופעות לוואי
4.8 Undesirable effects The adverse reactions below are classified where appropriate by system organ class and frequency according to the following convention: Very common: ≥ 1/10 Common: ≥ 1/100, < 1/10 Uncommon: ≥ 1/1,000, < 1/100 Rare: ≥ 1/10,000, < 1/1,000 Very rare: < 1/10,000 Not known: cannot be estimated from the available data In clinical trials with losartan potassium salt and hydrochlorothiazide, no adverse reactions peculiar to this combination of substances were observed. The adverse reactions were restricted to those which were formerly observed with losartan potassium salt and/or hydrochlorothiazide. In controlled clinical trials for essential hypertension, dizziness was the only adverse reaction reported as substance-related that occurred with an incidence greater than placebo in 1% or more of patients treated with losartan and hydrochlorothiazide. Next to these effects, there are further adverse reactions reported after the introduction of the product to the market as follows: System organ class Adverse reaction Frequency Hepato-biliary disorders hepatitis rare Investigations hyperkalaemia, elevation of ALT rare The adverse reactions that have been seen with one of the individual components and may be potential adverse reactions with losartan potassium/hydrochlorothiazide are the following: Losartan: The following adverse reactions have been reported for losartan in clinical studies and in post- marketing experience: System organ class Adverse reaction Frequency Blood and lymphatic anaemia, Henoch-Schönlein purpura, uncommon system disorders ecchymosis, haemolysis thrombocytopaenia not known System organ class Adverse reaction Frequency Cardiac disorders hypotension, orthostatic hypotension, uncommon sternalgia, angina pectoris, grade II-AV block, cerebrovascular event, myocardial infarction, palpitation, arrhythmias (atrial fibrillations, sinus bradycardia, tachycardia, ventricular tachycardia, ventricular fibrillation) Ear and labyrinth disorders vertigo, tinnitus uncommon Eye disorders blurred vision, burning/stinging in the eye, uncommon conjunctivitis, decrease in visual acuity Gastrointestinal disorders abdominal pain, nausea, diarrhea, dyspepsia common constipation, dental pain, dry mouth, uncommon flatulence, gastritis, vomiting, obstipation pancreatitis not known General disorders and asthenia, fatigue, chest pain common administration site facial oedema, oedema, fever uncommon conditions flu-like symptoms, malaise not known Hepatobiliary disorders liver function abnormalities not known Immune system disorders hypersensitivity: anaphylactic reactions, rare angioedema including swelling of the larynx and glottis causing airway obstruction and/or swelling of the face, lips, pharynx, and/or tongue; in some of these patients angioedema had been reported in the past in connection with the administration of other medicines, including ACE inhibitors; Metabolism and nutrition anorexia, gout uncommon disorders Musculoskeletal and muscle cramp, back pain, leg pain, myalgia common connective tissue disorders arm pain, joint swelling, knee pain, uncommon musculoskeletal pain, shoulder pain, stiffness, arthralgia, arthritis, coxalgia, fibromyalgia, muscle weakness rhabdomyolysis not known Nervous system disorders headache, dizziness common nervousness, paraesthesia, peripheral uncommon neuropathy, tremor, migraine, syncope dysgeusia not known System organ class Adverse reaction Frequency Psychiatric disorders insomnia common anxiety, anxiety disorder, panic disorder, uncommon confusion, depression, abnormal dreams, sleep disorder, somnolence, memory impairment Renal and urinary renal impairment, renal failure common disorders nocturia, urinary frequency, urinary tract uncommon infection Reproductive system and decreased libido, erectile uncommon breast disorders dysfunction/impotence Respiratory, thoracic and cough, upper respiratory infection, nasal common mediastinal disorders congestion, sinusitis, sinus disorder pharyngeal discomfort, pharyngitis, laryngitis, uncommon dyspnoea, bronchitis, epistaxis, rhinitis, respiratory congestion Skin and subcutaneous alopecia, dermatitis, dry skin, erythema, uncommon tissue disorders flushing, photosensitivity, pruritus, rash, urticaria, sweating Vascular disorders vasculitis uncommon dose-related orthostatic effects not known Investigations hyperkalaemia, mild reduction of haematocrit common and haemoglobin, hypoglycaemia mild increase in urea and creatinine serum uncommon levels increase in hepatic enzymes and bilirubin very rare hyponatraemia non known Hydrochlorothiazide System organ class Adverse reaction Frequency Blood and lymphatic agranulocytosis, aplastic anaemia, haemolytic uncommon system disorders anaemia, leukopenia, purpura, thrombocytopaenia Immune system disorders anaphylactic reaction rare Metabolism and nutrition anorexia, hyperglycaemia, hyperuricaemia, uncommon disorders hypokalaemia, hyponatraemia Psychiatric disorders insomnia uncommon Nervous system disorders cephalalgia common Eye disorders transient blurred vision, xanthopsia uncommon choroidal effusion, acute myopia, acute angle- not known closure glaucoma Vascular disorders necrotizing angiitis (vasculitis, cutaneous uncommon vasculitis) System organ class Adverse reaction Frequency Respiratory, thoracic and respiratory disorders including pneumonitis uncommon mediastinal disorders and pulmonary oedema acute respiratory distress syndrome (ARDS) very rare (see section 4.4) Gastrointestinal disorders sialoadenitis, spasms, stomach irritation, uncommon nausea, vomiting, diarrhoea, constipation Hepato-biliary disorders icterus (intrahepatic cholestasis), pancreatitis uncommon Skin and subcutaneous photosensitivity, urticaria, toxic epidermal uncommon tissue disorders necrolysis cutaneous lupus erythematosus not known Musculoskeletal and muscle cramps uncommon connective tissue disorders Neoplasms benign, Non-melanoma skin cancer (basal cell not known malignant and unspecified carcinoma and squamous cell carcinoma) (incl. cysts and polyps) Renal and urinary glycosuria, interstitial nephritis, renal uncommon disorders dysfunction, renal failure General disorders and fever, dizziness uncommon administration site conditions Description of Selected Adverse Reactions Non-melanoma skin cancer: Based on available data from epidemiological studies, cumulative dose dependent association between hydrochlorothiazide and NMSC has been observed (see also sections 4.4 and 5.1). Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorization of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Any suspected adverse events should be reported to the Ministry of Health according to the National Regulation by using an online form: https://sideeffects.health.gov.il
פרטי מסגרת הכללה בסל
התרופה האמורה תינתן לחולים הסובלים מיתר לחץ דם או אי ספיקת לב הסובלים בנוסף מרגישות לטיפול בתכשירים השייכים למשפחת מעכבי ACE או שפיתחו תופעות לוואי לטיפול כאמור
מסגרת הכללה בסל
התוויות הכלולות במסגרת הסל
התוויה | תאריך הכללה | תחום קליני | Class Effect | מצב מחלה |
---|---|---|---|---|
חולה הסובל מיתר לחץ דם או אי ספיקת לב הסובל בנוסף מרגישות לטיפול בתכשירים השייכים למשפחת מעכבי ACE או שפיתח תופעות לוואי לטיפול | ||||
OLMESARTAN MEDOXOMIL | ||||
VALSARTAN | ||||
LOSARTAN | ||||
IRBESARTAN | ||||
CANDESARTAN | ||||
טיפול בחלבון בשתן מתחת ל-1 גרם ומעל ל-30 מ"ג, עבור חולה שלא סובל מיתר לחץ דם או אי ספיקת לב, הסובל בנוסף מרגישות לטיפול בתכשירים השייכים למשפחת מעכבי ACE או שפיתח תופעות לוואי לטיפול כאמור. | ||||
חולה הסובל מפרוטאינוריה מעל 1 גרם, בשילוב עם מעכבי ACE |
שימוש לפי פנקס קופ''ח כללית 1994
לא צוין
תאריך הכללה מקורי בסל
01/03/2002
הגבלות
תרופה מוגבלת לרישום ע'י רופא מומחה או הגבלה אחרת
מידע נוסף
עלון מידע לצרכן
02.06.19 - עלון לצרכן אנגלית 30.08.22 - עלון לצרכן אנגלית 02.06.19 - עלון לצרכן עברית 30.08.22 - עלון לצרכן עברית 02.06.19 - עלון לצרכן ערבית 15.12.21 - עלון לצרכן ערבית 11.10.22 - עלון לצרכן ערבית 05.12.22 - עלון לצרכן אנגלית 05.12.22 - עלון לצרכן עברית 08.01.23 - עלון לצרכן ערבית 04.05.14 - החמרה לעלון 21.01.20 - החמרה לעלון 18.10.21 - החמרה לעלון 30.08.22 - החמרה לעלון 05.12.22 - החמרה לעלוןלתרופה במאגר משרד הבריאות
אוקסאאר פלוס